Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Sponsor: IPSEN Biopharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS2820
U.S. Govt. ID: NCT03946527
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the effectiveness of the therapy to be administered (how well it works) and the safety profile (if it has any unwanted effects on you that you can feel or on laboratory tests that are obtained) of lanreotide (a somatostatin analog (a hormone produced by the hypothalamus and some other tissues such as the pancreas and the gastrointestinal tract) that interferes with tumor growth) in subjects with advanced/metastatic pheochromocytoma or paraganglioma. You are being asked to participate in this study because you have metastatic pheochromocytoma or metastatic paraganglioma and you have never been treated with a somatostatin analogs. Approximately 40 individuals will be asked to participate in this study.
This study is closed
Antonio Fojo, MD, PhD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have cancerous paraganglioma or pheochromocytoma and either evidence of spreading or is unable to be removed? Yes No
Do you have life expectancy of greater than 12 weeks? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator